作者@article {JaisRCT1885 ={洁,泽维尔Brenot, Philippe and Bouvaist, H{\'e}l{\`e}ne and Canuet, Matthieu and Chabanne, C{\'e}line and Chaouat, Ari and Cottin, Vincent and De Groote, Pascal and Dromer, Claire and Favrolt, Nicolas and Garcia Alonso, Carlos and G{\'e}rardin, Benoit and Horeau-Langlard, Delphine and Jevnikar, Mitja and Magro, Pascal and Montani, David and Parent, Florence and Pison, Christophe and Pr{\'e}vot, Gr{\'e}goire and Renard, S{\'e}bastien and Savale, Laurent and Simon, Anne Claire and Sitbon, Olivier and Tresorier, Romain and Tromeur, C{\'e}cile and Agostini, H{\'e}l{\`e}ne and Piedvache, C{\'e}line and Fadel, Elie and Humbert, Marc and Simonneau, G{\'e}rald}, title = {Late Breaking Abstract - Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study}, volume = {54}, number = {suppl 63}, elocation-id = {RCT1885}, year = {2019}, doi = {10.1183/13993003.congress-2019.RCT1885}, publisher = {European Respiratory Society}, abstract = {Background: Medical therapy with riociguat and balloon pulmonary angioplasty (BPA) are two therapeutic options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Controlled studies comparing these two treatments are lacking.Methods: The multicenter, randomised, controlled RACE trial evaluated the efficacy and safety of riociguat versus BPA in newly diagnosed and treatment-na{\"\i}ve patients with CTEPH adjudicated as inoperable. Patients identified as WHO functional class (FC) I-IV with a pulmonary vascular resistance (PVR) \>320 dyn.s/cm5 were randomly assigned, in a 1:1 ratio, to receive a treatment with riociguat or BPA. The primary endpoint was resting PVR at week 26, expressed as percentage of PVR at baseline. Secondary endpoints included changes from baseline in 6-min walk distance (6MWD), WHO FC, NT-proBNP, time to clinical worsening, and safety.Results: Between January 2016 and January 2019, 105 patients were randomised in 14 centers belonging to the French Pulmonary Hypertension Network: 53 to riociguat, 52 to BPA. Baseline characteristics are depicted in the table. The full study results will be available in June 2019.View this table:Conclusion: RACE study will provide important informations on the effect of riociguat compared to that of BPA as first-line therapy in treatment-na{\"\i}ve patients with inoperable CTEPH.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, RCT1885.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/54/suppl_63/RCT1885}, eprint = {//www.qdcxjkg.com/content}, journal = {European Respiratory Journal} }